Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.033%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Germany targets doctors, border states in vaccination drive

Fri, 19th Mar 2021 12:41

* Merkel, state leaders agree measures to speed vaccinations

* Germany's vaccination rate lags other countries

* Minister warns vaccinations alone won't contain 3rd wave
(Adds further comments, background)

BERLIN, March 19 (Reuters) - Germany will supply general
practitioners with vaccines and deliver additional doses to
regions on the Czech and French borders as it seeks to get its
campaign back on track following a three-day pause in using the
AstraZeneca shot.

"The motto is vaccinate, vaccinate, vaccinate," German
Chancellor Angela Merkel said after a meeting with the leaders
of Germany's 16 federal states.

Case numbers have been rising in Germany, driven by an
easing of restrictions in recent weeks just as a more
transmissible variant of the virus has spread, underlining the
need to accelerate vaccinations to protect the vulnerable.

The suspension of the AstraZeneca vaccine was the latest
hurdle in Germany's vaccination campaign, which has been plagued
by delivery delays and news reports of side-effects. As of
Friday, just 8.5% of the population had received a first shot,
far behind other countries like the United States and Britain.

"I think we have a good chance of offering a vaccine to
every resident by the end of the summer," Merkel said.

Health Minister Jens Spahn earlier on Friday warned that
vaccinations alone would not be able to contain the third wave
of the pandemic as there are not enough doses, and said
restrictions that were lifted may have to be reimposed to
contain the spread of the virus.

"The rising case numbers may mean that we cannot take
further opening steps in the weeks to come. On the contrary, we
may even have to take steps backwards," Spahn said.

Merkel and the state leaders are due to meet again on Monday
to discuss extending a lockdown that has been in place since
mid-December, as well as a reversal of plans to gradually
re-open the economy.

YOUNGER WOMEN

Germany resumed administering AstraZeneca jabs on Friday,
with state leaders saying they were ready to quickly catch up on
lost time.

The premier of the southwestern German state of
Baden-Wuerttemberg, Winfried Kretschmann, 72, received an
AstraZeneca vaccination Friday, in a move to shore up
confidence.

But Bodo Ramelow, the premier of Thuringia in eastern
Germany, said he would not advise his wife, who needs to use
blood thinners due to a risk of thrombosis, to get the
AstraZeneca shot although he would do so himself.

In Germany, eight people were diagnosed with cerebral venous
sinus thrombosis (CVST) within about two weeks of being
vaccinated. They were among the 1.6 million recipients of the
shot as of Wednesday, with CVST cases higher among women.

Spahn said earlier he hoped vaccinations could take place in
doctors' practices from April 19 at the latest, but warned that
supply would remain restricted.

Germany expects to receive 15 million doses of the
AstraZeneca vaccine in the second quarter, a few million fewer
than initially expected, he said.

Spahn also spoke out in favour of signing a supply deal for
the Russian Sputnik V vaccine for COVID-19, but said there
needed to be greater clarity on the quantities available.

Merkel said Germany would consider a national order of
Sputnik, though she would prefer European Union-wide
procurement.

(Reporting by Caroline Copley, Thomas Escritt, Paul Carrel;
Writing by Caroline Copley and Maria Sheahan; Editing by Paul
Simao and Kirsti Knolle)

More News
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.